Tag: malignant pleural effusion market share

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Malignant Pleural Effusion Market Expected To Reach $6.51 Billion By 2030 At 6.6% CAGR

The malignant pleural effusion sector experienced robust expansion lately. Projections indicate a rise from $4.73 billion in 2025 to $5.05 billion in 2026, reflecting a compound annual growth rate of 6.8%. Historical expansion drivers included a greater occurrence of metastatic cancers, a scarcity of treatment methodologies offering cures, the necessity for frequent thoracentesis to alleviate symptoms, the expansion of inpatient cancer treatment facilities, and the progressive acceptance of pleurodesis procedures.

The market for malignant pleural effusion is poised for substantial expansion over the coming years, projected to reach $6.52 billion by 2030, reflecting a compound annual growth rate of 6.6%. This anticipated growth trajectory is fueled by an increasing incidence of cancer globally, coupled with ongoing innovations in pleural catheter technology, a discernible shift towards outpatient and home-care models, enhanced precision in diagnostic imaging techniques, and a heightened demand for therapeutic interventions prioritizing patient quality of life. Key developments anticipated within this period involve a greater adoption of indwelling pleural catheters for sustained management, a trend favoring less invasive procedures for pleural conditions, the increasing incorporation of systemic cancer treatments into MPE management strategies, a stronger emphasis on relief of symptoms and palliative care, and the broader application of imaging-guided methods for both diagnosis and treatment.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22047&type=smp

Malignant Pleural Effusion Market Growth Factors Supporting Long-Term Expansion

An escalation in lung cancer diagnoses is anticipated to fuel the expansion of the malignant pleural effusion market. Lung cancer, defined by the uncontrolled proliferation of aberrant cells within the lungs, can manifest as tumors that disrupt normal pulmonary function. Factors such as smoking and tobacco consumption are primary contributors to the increasing incidence of lung cancer, as extended exposure to cigarette constituents inflicts damage on lung tissues, instigates genetic alterations, and fosters the unrestrained growth of malignant cells, thereby substantially elevating the risk of developing the ailment. Malignant pleural effusion signifies a more advanced stage of lung cancer, characterized by the dissemination of the tumor into the pleural space, leading to compromised respiratory capacity and a less favorable prognosis. Illustratively, the American Cancer Society Facts and Figures reported that in the United States, estimated new cases of lung and bronchus cancer were 236,740 in 2022 and projected to be 238,340 in 2023, with corresponding death estimates of 130,180 in 2022 and 127,070 in 2023. Consequently, the growing prevalence of lung cancer is directly stimulating the growth of the malignant pleural effusion market.

Advances in healthcare infrastructure are poised to catalyze the expansion of the malignant pleural effusion market. This infrastructure encompasses the physical, technological, and organizational frameworks essential for healthcare delivery, including medical facilities, sophisticated equipment, robust IT systems, and skilled personnel. Such improvements are driven by the imperative for more effective disease management, collectively enhancing accessibility to healthcare, operational efficiency, and the overall caliber of medical services. By providing access to cutting-edge medical technologies, well-resourced healthcare settings, and specialized medical expertise, enhanced healthcare infrastructure facilitates more accurate diagnosis, effective treatment, and proficient management of malignant pleural effusion, ultimately leading to improved patient health outcomes. As an illustration, the American Health Care Association noted a rise in the number of hospitals across the United States, increasing by 0.591% from 6,093 to 6,129 between May 2022 and May 2023. Therefore, the ongoing enhancements in healthcare infrastructure are acting as a key driver for the growth observed in the malignant pleural effusion market.

Malignant Pleural Effusion Market Segmentation And Category Breakdown

The malignant pleural effusion market covered in this report is segmented –

1) By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter

2) By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy

3) By End Users: Hospitals, Ambulatory Clinics, Other End Users

Subsegments:

1) By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy

2) By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis

3) By Thoracic Drainage And Pleurodesis: Chemical Pleurodesis, Mechanical Pleurodesis

4) By Indwelling Pleural Catheter: Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter

Malignant Pleural Effusion Market Industry Trends Shaping Future Revenue Growth

In the realm of the malignant pleural effusion market, leading enterprises are concentrating their efforts on pioneering novel solutions, exemplified by the creation of fully implantable automatic fluid-shunt devices, aiming to enhance patient well-being and decrease the frequency of hospitalizations. These sophisticated medical devices, once surgically placed within the body, possess the capability to autonomously evacuate surplus pleural fluid from the lungs into the abdominal cavity or an alternative location, thereby alleviating symptoms such as shortness of breath, diminishing the necessity for repeated medical interventions, and ultimately elevating the patient’s overall quality of life. A notable illustration of this advancement is the introduction of the ACES Automatic Continuous Effusion Shunt System by Pleural Dynamics, a medical device firm based in the United States, in October of 2023. This ingenious system incorporates a flexible, durable pump chamber designed for subcutaneous implantation between the patient’s ribs, connected by catheters to both the pleural space and the peritoneal space. The patient’s natural breathing motion alternately compresses and expands the internal pump extension situated between the ribs, propelling fluid from the pleural cavity into the abdomen for natural reabsorption; furthermore, the system includes an external compression extension that permits manual activation when needed. The primary advantages of this innovative technology encompass its completely internal placement, dispensing with external drainage apparatus or collection containers, its automatic fluid transfer mechanism powered by the patient’s respiration, a brief hospital stay requirement for the implantation procedure, and the provision of persistent relief from the discomfort associated with recurring effusions.

Malignant Pleural Effusion Market Competitive Analysis Of Major Industry Participants

Major companies operating in the malignant pleural effusion market are Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc, Argon Medical Devices Inc, B Braun SE, Medtronic plc, Smiths Medical, Teleflex Incorporated, Cardinal Health Inc, Getinge AB, AngioDynamics Inc, Rocket Medical plc, Redax SpA, Atrium Medical Corporation, PolyMedicure Ltd, Troge Medical GmbH, Vygon SA, ICU Medical Inc, ConvaTec Group plc, Baxter International Inc

Access The Complete Malignant Pleural Effusion Market Report:

https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report

Malignant Pleural Effusion Market Geographic Distribution And Regional Opportunities

North Americawas the largest region in the malignant pleural effusion market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Malignant Pleural Effusion Market Expected To Reach $6.51 Billion By 2030 At 6.6% CAGR

The malignant pleural effusion sector experienced robust expansion lately. Projections indicate a rise from $4.73 billion in 2025 to $5.05 billion in 2026, reflecting a compound annual growth rate of 6.8%. Historical expansion drivers included a greater occurrence of metastatic cancers, a scarcity of treatment methodologies offering cures, the necessity for frequent thoracentesis to alleviate symptoms, the expansion of inpatient cancer treatment facilities, and the progressive acceptance of pleurodesis procedures.

The market for malignant pleural effusion is poised for substantial expansion over the coming years, projected to reach $6.52 billion by 2030, reflecting a compound annual growth rate of 6.6%. This anticipated growth trajectory is fueled by an increasing incidence of cancer globally, coupled with ongoing innovations in pleural catheter technology, a discernible shift towards outpatient and home-care models, enhanced precision in diagnostic imaging techniques, and a heightened demand for therapeutic interventions prioritizing patient quality of life. Key developments anticipated within this period involve a greater adoption of indwelling pleural catheters for sustained management, a trend favoring less invasive procedures for pleural conditions, the increasing incorporation of systemic cancer treatments into MPE management strategies, a stronger emphasis on relief of symptoms and palliative care, and the broader application of imaging-guided methods for both diagnosis and treatment.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22047&type=smp

Malignant Pleural Effusion Market Growth Factors Supporting Long-Term Expansion

An escalation in lung cancer diagnoses is anticipated to fuel the expansion of the malignant pleural effusion market. Lung cancer, defined by the uncontrolled proliferation of aberrant cells within the lungs, can manifest as tumors that disrupt normal pulmonary function. Factors such as smoking and tobacco consumption are primary contributors to the increasing incidence of lung cancer, as extended exposure to cigarette constituents inflicts damage on lung tissues, instigates genetic alterations, and fosters the unrestrained growth of malignant cells, thereby substantially elevating the risk of developing the ailment. Malignant pleural effusion signifies a more advanced stage of lung cancer, characterized by the dissemination of the tumor into the pleural space, leading to compromised respiratory capacity and a less favorable prognosis. Illustratively, the American Cancer Society Facts and Figures reported that in the United States, estimated new cases of lung and bronchus cancer were 236,740 in 2022 and projected to be 238,340 in 2023, with corresponding death estimates of 130,180 in 2022 and 127,070 in 2023. Consequently, the growing prevalence of lung cancer is directly stimulating the growth of the malignant pleural effusion market.

Advances in healthcare infrastructure are poised to catalyze the expansion of the malignant pleural effusion market. This infrastructure encompasses the physical, technological, and organizational frameworks essential for healthcare delivery, including medical facilities, sophisticated equipment, robust IT systems, and skilled personnel. Such improvements are driven by the imperative for more effective disease management, collectively enhancing accessibility to healthcare, operational efficiency, and the overall caliber of medical services. By providing access to cutting-edge medical technologies, well-resourced healthcare settings, and specialized medical expertise, enhanced healthcare infrastructure facilitates more accurate diagnosis, effective treatment, and proficient management of malignant pleural effusion, ultimately leading to improved patient health outcomes. As an illustration, the American Health Care Association noted a rise in the number of hospitals across the United States, increasing by 0.591% from 6,093 to 6,129 between May 2022 and May 2023. Therefore, the ongoing enhancements in healthcare infrastructure are acting as a key driver for the growth observed in the malignant pleural effusion market.

Malignant Pleural Effusion Market Segmentation And Category Breakdown

The malignant pleural effusion market covered in this report is segmented –

1) By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter

2) By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy

3) By End Users: Hospitals, Ambulatory Clinics, Other End Users

Subsegments:

1) By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy

2) By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis

3) By Thoracic Drainage And Pleurodesis: Chemical Pleurodesis, Mechanical Pleurodesis

4) By Indwelling Pleural Catheter: Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter

Malignant Pleural Effusion Market Industry Trends Shaping Future Revenue Growth

In the realm of the malignant pleural effusion market, leading enterprises are concentrating their efforts on pioneering novel solutions, exemplified by the creation of fully implantable automatic fluid-shunt devices, aiming to enhance patient well-being and decrease the frequency of hospitalizations. These sophisticated medical devices, once surgically placed within the body, possess the capability to autonomously evacuate surplus pleural fluid from the lungs into the abdominal cavity or an alternative location, thereby alleviating symptoms such as shortness of breath, diminishing the necessity for repeated medical interventions, and ultimately elevating the patient’s overall quality of life. A notable illustration of this advancement is the introduction of the ACES Automatic Continuous Effusion Shunt System by Pleural Dynamics, a medical device firm based in the United States, in October of 2023. This ingenious system incorporates a flexible, durable pump chamber designed for subcutaneous implantation between the patient’s ribs, connected by catheters to both the pleural space and the peritoneal space. The patient’s natural breathing motion alternately compresses and expands the internal pump extension situated between the ribs, propelling fluid from the pleural cavity into the abdomen for natural reabsorption; furthermore, the system includes an external compression extension that permits manual activation when needed. The primary advantages of this innovative technology encompass its completely internal placement, dispensing with external drainage apparatus or collection containers, its automatic fluid transfer mechanism powered by the patient’s respiration, a brief hospital stay requirement for the implantation procedure, and the provision of persistent relief from the discomfort associated with recurring effusions.

Malignant Pleural Effusion Market Competitive Analysis Of Major Industry Participants

Major companies operating in the malignant pleural effusion market are Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc, Argon Medical Devices Inc, B Braun SE, Medtronic plc, Smiths Medical, Teleflex Incorporated, Cardinal Health Inc, Getinge AB, AngioDynamics Inc, Rocket Medical plc, Redax SpA, Atrium Medical Corporation, PolyMedicure Ltd, Troge Medical GmbH, Vygon SA, ICU Medical Inc, ConvaTec Group plc, Baxter International Inc

Access The Complete Malignant Pleural Effusion Market Report:

https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report

Malignant Pleural Effusion Market Geographic Distribution And Regional Opportunities

North Americawas the largest region in the malignant pleural effusion market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Malignant Pleural Effusion Market Expected To Reach $6.51 Billion By 2030 At 6.6% CAGR

The malignant pleural effusion sector experienced robust expansion lately. Projections indicate a rise from $4.73 billion in 2025 to $5.05 billion in 2026, reflecting a compound annual growth rate of 6.8%. Historical expansion drivers included a greater occurrence of metastatic cancers, a scarcity of treatment methodologies offering cures, the necessity for frequent thoracentesis to alleviate symptoms, the expansion of inpatient cancer treatment facilities, and the progressive acceptance of pleurodesis procedures.

The market for malignant pleural effusion is poised for substantial expansion over the coming years, projected to reach $6.52 billion by 2030, reflecting a compound annual growth rate of 6.6%. This anticipated growth trajectory is fueled by an increasing incidence of cancer globally, coupled with ongoing innovations in pleural catheter technology, a discernible shift towards outpatient and home-care models, enhanced precision in diagnostic imaging techniques, and a heightened demand for therapeutic interventions prioritizing patient quality of life. Key developments anticipated within this period involve a greater adoption of indwelling pleural catheters for sustained management, a trend favoring less invasive procedures for pleural conditions, the increasing incorporation of systemic cancer treatments into MPE management strategies, a stronger emphasis on relief of symptoms and palliative care, and the broader application of imaging-guided methods for both diagnosis and treatment.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22047&type=smp

Malignant Pleural Effusion Market Growth Factors Supporting Long-Term Expansion

An escalation in lung cancer diagnoses is anticipated to fuel the expansion of the malignant pleural effusion market. Lung cancer, defined by the uncontrolled proliferation of aberrant cells within the lungs, can manifest as tumors that disrupt normal pulmonary function. Factors such as smoking and tobacco consumption are primary contributors to the increasing incidence of lung cancer, as extended exposure to cigarette constituents inflicts damage on lung tissues, instigates genetic alterations, and fosters the unrestrained growth of malignant cells, thereby substantially elevating the risk of developing the ailment. Malignant pleural effusion signifies a more advanced stage of lung cancer, characterized by the dissemination of the tumor into the pleural space, leading to compromised respiratory capacity and a less favorable prognosis. Illustratively, the American Cancer Society Facts and Figures reported that in the United States, estimated new cases of lung and bronchus cancer were 236,740 in 2022 and projected to be 238,340 in 2023, with corresponding death estimates of 130,180 in 2022 and 127,070 in 2023. Consequently, the growing prevalence of lung cancer is directly stimulating the growth of the malignant pleural effusion market.

Advances in healthcare infrastructure are poised to catalyze the expansion of the malignant pleural effusion market. This infrastructure encompasses the physical, technological, and organizational frameworks essential for healthcare delivery, including medical facilities, sophisticated equipment, robust IT systems, and skilled personnel. Such improvements are driven by the imperative for more effective disease management, collectively enhancing accessibility to healthcare, operational efficiency, and the overall caliber of medical services. By providing access to cutting-edge medical technologies, well-resourced healthcare settings, and specialized medical expertise, enhanced healthcare infrastructure facilitates more accurate diagnosis, effective treatment, and proficient management of malignant pleural effusion, ultimately leading to improved patient health outcomes. As an illustration, the American Health Care Association noted a rise in the number of hospitals across the United States, increasing by 0.591% from 6,093 to 6,129 between May 2022 and May 2023. Therefore, the ongoing enhancements in healthcare infrastructure are acting as a key driver for the growth observed in the malignant pleural effusion market.

Malignant Pleural Effusion Market Segmentation And Category Breakdown

The malignant pleural effusion market covered in this report is segmented –

1) By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter

2) By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy

3) By End Users: Hospitals, Ambulatory Clinics, Other End Users

Subsegments:

1) By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy

2) By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis

3) By Thoracic Drainage And Pleurodesis: Chemical Pleurodesis, Mechanical Pleurodesis

4) By Indwelling Pleural Catheter: Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter

Malignant Pleural Effusion Market Industry Trends Shaping Future Revenue Growth

In the realm of the malignant pleural effusion market, leading enterprises are concentrating their efforts on pioneering novel solutions, exemplified by the creation of fully implantable automatic fluid-shunt devices, aiming to enhance patient well-being and decrease the frequency of hospitalizations. These sophisticated medical devices, once surgically placed within the body, possess the capability to autonomously evacuate surplus pleural fluid from the lungs into the abdominal cavity or an alternative location, thereby alleviating symptoms such as shortness of breath, diminishing the necessity for repeated medical interventions, and ultimately elevating the patient’s overall quality of life. A notable illustration of this advancement is the introduction of the ACES Automatic Continuous Effusion Shunt System by Pleural Dynamics, a medical device firm based in the United States, in October of 2023. This ingenious system incorporates a flexible, durable pump chamber designed for subcutaneous implantation between the patient’s ribs, connected by catheters to both the pleural space and the peritoneal space. The patient’s natural breathing motion alternately compresses and expands the internal pump extension situated between the ribs, propelling fluid from the pleural cavity into the abdomen for natural reabsorption; furthermore, the system includes an external compression extension that permits manual activation when needed. The primary advantages of this innovative technology encompass its completely internal placement, dispensing with external drainage apparatus or collection containers, its automatic fluid transfer mechanism powered by the patient’s respiration, a brief hospital stay requirement for the implantation procedure, and the provision of persistent relief from the discomfort associated with recurring effusions.

Malignant Pleural Effusion Market Competitive Analysis Of Major Industry Participants

Major companies operating in the malignant pleural effusion market are Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc, Argon Medical Devices Inc, B Braun SE, Medtronic plc, Smiths Medical, Teleflex Incorporated, Cardinal Health Inc, Getinge AB, AngioDynamics Inc, Rocket Medical plc, Redax SpA, Atrium Medical Corporation, PolyMedicure Ltd, Troge Medical GmbH, Vygon SA, ICU Medical Inc, ConvaTec Group plc, Baxter International Inc

Access The Complete Malignant Pleural Effusion Market Report:

https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report

Malignant Pleural Effusion Market Geographic Distribution And Regional Opportunities

North Americawas the largest region in the malignant pleural effusion market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Growth In Market Size Of The Malignant Pleural Effusion Market During 2026–2030?

The malignant pleural effusion market size has experienced significant growth in recent years. Its expansion is projected to move from $4.73 billion in 2025 to $5.05 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. Historically, this growth can be ascribed to several key factors, including the rising incidence of metastatic cancers, the limited availability of curative treatment options, the necessity for repeated thoracentesis for symptom control, the growth of hospital-based cancer care, and the gradual implementation of pleurodesis techniques.

The malignant pleural effusion market size is projected to experience robust growth in the upcoming years. It is predicted to expand to $6.52 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period can be attributed to several factors including the increasing global prevalence of cancer, continuous advancements in pleural catheter technologies, a heightened emphasis on outpatient and home-based care options, improved precision in diagnostic imaging, and a rising demand for treatments centered on enhancing quality of life. Significant trends identified for this period encompass a greater utilization of indwelling pleural catheters for sustained management, a growing preference for less invasive pleural interventions, the broader integration of systemic cancer therapies in malignant pleural effusion management, an increased focus on approaches for symptom relief and palliative care, and the expansion of diagnostic and therapeutic procedures guided by imaging.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22047&type=smp

Which Drivers Are Advancing The Malignant Pleural Effusion Market Growth?

The increasing incidence of lung cancer is anticipated to propel the growth of the malignant pleural effusion market. Lung cancer is a condition marked by the uncontrolled multiplication of abnormal cells in the lungs, forming tumors that disrupt normal lung function. The rise in lung cancer cases is linked to smoking and tobacco consumption, as extended exposure to detrimental chemicals in cigarettes harms lung tissues, initiates genetic mutations, and encourages the unregulated growth of cancerous cells, substantially heightening the likelihood of developing the disease. Malignant pleural effusion indicates advanced lung cancer progression by enabling tumor spread within the pleural cavity, resulting in deteriorated respiratory function and a less favorable prognosis. For instance, in January 2023, the American Cancer Society Facts and Figures, a US-based professional organizations company, reported estimated new lung and bronchus cancer cases were 236,740 in 2022 and 238,340 in 2023, while estimated deaths stood at 130,180 in 2022 and 127,070 in 2023. Consequently, the rising cases of lung cancer are driving the expansion of the malignant pleural effusion market.

What Are The Major Segment Categories Within The Malignant Pleural Effusion Market?

The malignant pleural effusion market covered in this report is segmented –

1) By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter

2) By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy

3) By End Users: Hospitals, Ambulatory Clinics, Other End Users

Subsegments:

1) By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy

2) By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis

3) By Thoracic Drainage And Pleurodesis: Chemical Pleurodesis, Mechanical Pleurodesis

4) By Indwelling Pleural Catheter: Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter

What Trends Are Affecting The Growth Of The Malignant Pleural Effusion Market?

Leading companies operating in the malignant pleural effusion market are concentrating on developing innovative products, such as fully-implantable automatic fluid-shunt devices, to enhance patient comfort and decrease hospital visits. A fully-implantable automatic fluid-shunt device is a medical apparatus surgically placed within the body that automatically drains excess pleural fluid from the lungs into the abdomen or another region, thereby helping to relieve breathlessness symptoms, reduce the need for repeated hospital procedures, and improve the patient’s quality of life. For instance, in October 2023, Pleural Dynamics, a US-based medical device company, launched the ACES Automatic Continuous Effusion Shunt System. This device is composed of a resilient flexible pump chamber implanted under the skin between the ribs, with one catheter in the pleural space and another in the peritoneal space. As the patient breathes, the internal pump extension is compressed and decompressed between adjacent ribs, propelling fluid from the pleural cavity to the abdomen where it is reabsorbed; the system also permits manual activation through an external compression extension. Key features include a fully implantable design, no external drainage tubing or suction bottles, a breathing-powered automatic pumping function, minimal hospital stay for implantation, and continuous symptom relief from recurrent effusions.

Which Key Players Are Active In The Malignant Pleural Effusion Market?

Major companies operating in the malignant pleural effusion market are Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc, Argon Medical Devices Inc, B Braun SE, Medtronic plc, Smiths Medical, Teleflex Incorporated, Cardinal Health Inc, Getinge AB, AngioDynamics Inc, Rocket Medical plc, Redax SpA, Atrium Medical Corporation, PolyMedicure Ltd, Troge Medical GmbH, Vygon SA, ICU Medical Inc, ConvaTec Group plc, Baxter International Inc

Access The Complete Malignant Pleural Effusion Market Report:

https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report

Which Region Is The Dominant Market In The Malignant Pleural Effusion Market?

North America was the largest region in the malignant pleural effusion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Malignant Pleural Effusion Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=22047&type=smp

Browse Through More Reports Similar to the Global Malignant Pleural Effusion Market 2026, By The Business Research Company

Acoustic Neuroma Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/acoustic-neuroma-global-market-report

Paraganglioma Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/paraganglioma-global-market-report

Adult Malignant Glioma Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Malignant Pleural Effusion Market Expected To Scale Between 2026 And 2030?

The malignant pleural effusion market size has experienced strong growth in recent years. It is projected to increase from $4.73 billion in 2025 to $5.05 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. This historical growth can be attributed to factors such as the rising incidence of metastatic cancers, the limited curative treatment options available, the reliance on repeated thoracentesis for symptom management, the expansion of hospital-based cancer care, and the progressive adoption of pleurodesis techniques.

The malignant pleural effusion market is projected to experience robust expansion over the coming years. By 2030, its valuation is anticipated to reach $6.52 billion, exhibiting a compound annual growth rate (CAGR) of 6.6%. This projected growth during the forecast period is driven by several factors, including the increasing global incidence of cancer, continuous improvements in pleural catheter technologies, a greater focus on outpatient and home-based care models, enhanced precision in diagnostic imaging, and an escalating need for treatments prioritizing patient quality of life. Key developments expected within this period involve the rising adoption of indwelling pleural catheters for sustained management, a growing inclination towards minimally invasive pleural procedures, the broader incorporation of systemic cancer therapies into MPE management strategies, an increased emphasis on symptom alleviation and palliative care methods, and the wider application of imaging-guided diagnostic and treatment interventions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22047&type=smp

Which Strong Drivers Are Impacting The Malignant Pleural Effusion Market Growth?

An anticipated increase in lung cancer cases is poised to drive the growth of the Malignant Pleural Effusion Market in the foreseeable future. Lung cancer is a condition marked by the uncontrolled multiplication of abnormal cells within the lungs, which can develop into tumors and disrupt normal lung function. This rise in lung cancer cases is primarily linked to smoking and tobacco use, as prolonged exposure to harmful chemicals in cigarettes damages lung tissues, triggers genetic mutations, and fosters the unrestrained proliferation of cancerous cells, substantially increasing the risk of developing the disease. Malignant pleural effusion signifies advanced lung cancer progression by facilitating the spread of tumors within the pleural cavity, leading to impaired respiratory function and a less favorable prognosis. For instance, in January 2023, data from the American Cancer Society Facts and Figures, a US-based professional organizations company, estimated new lung and bronchus cancer cases at 236,740 in 2022 and 238,340 in 2023. During the same period, estimated deaths were 130,180 in 2022 and 127,070 in 2023. Consequently, the increasing incidence of lung cancer is a significant factor propelling the expansion of the Malignant Pleural Effusion Market. The enhancement of healthcare infrastructure is anticipated to drive the expansion of the Malignant Pleural Effusion Market in the future. Healthcare infrastructure refers to the foundational physical, technological, and organizational elements required for delivering medical services, including hospitals, clinics, specialized equipment, IT systems, and personnel. Improvements in this infrastructure are driven by the need for more effective disease management, contributing to greater healthcare accessibility, efficiency, and quality of care. Such advancements facilitate the diagnosis, treatment, and management of malignant pleural effusion by offering access to cutting-edge medical technologies, well-equipped facilities, and expert care, ultimately leading to improved patient outcomes. For instance, in May 2023, the American Health Care Association, a US-based nonprofit organization, noted a 0.591% increase in the number of hospitals in the United States from the preceding year, rising from 6,093 to 6,129. Therefore, the betterment of healthcare infrastructure is a key factor stimulating the growth of the Malignant Pleural Effusion Market.

How Is Segmentation Applied In The Malignant Pleural Effusion Market Segment Analysis?

The malignant pleural effusion market covered in this report is segmented –

1) By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter

2) By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy

3) By End Users: Hospitals, Ambulatory Clinics, Other End Users

Subsegments:

1) By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy

2) By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis

3) By Thoracic Drainage And Pleurodesis: Chemical Pleurodesis, Mechanical Pleurodesis

4) By Indwelling Pleural Catheter: Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter

Which Trends Are Contributing To Changes In The Malignant Pleural Effusion Market?

Leading companies in the malignant pleural effusion market are concentrating on developing advanced products, such as fully-implantable automatic fluid-shunt devices, to enhance patient comfort and decrease hospital visits. A fully-implantable automatic fluid-shunt device is a medical apparatus placed within the body that autonomously drains excess pleural fluid from the lungs into the abdomen or another region, thereby helping to relieve breathlessness, reduce the necessity for repeated hospital procedures, and improve the patient’s quality of life. For example, in October 2023, Pleural Dynamics, a US-based medical device company, introduced the ACES Automatic Continuous Effusion Shunt System. This device consists of a resilient, flexible pump chamber implanted beneath the skin between the ribs, with one catheter situated in the pleural space and another in the peritoneal space. As the patient inhales and exhales, the internal pump extension compresses and decompresses between adjacent ribs, propelling fluid from the pleural cavity to the abdomen where it is reabsorbed; additionally, the system permits manual activation via an external compression extension. Significant characteristics of this system include its entirely implantable design, absence of external drainage tubing or suction bottles, a pumping function that automatically activates with breathing, a short hospital stay for its placement, and continuous symptom relief for recurring effusions.

Who Are The Companies Participating In The Malignant Pleural Effusion Market Environment?

Major companies operating in the malignant pleural effusion market are Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc, Argon Medical Devices Inc, B Braun SE, Medtronic plc, Smiths Medical, Teleflex Incorporated, Cardinal Health Inc, Getinge AB, AngioDynamics Inc, Rocket Medical plc, Redax SpA, Atrium Medical Corporation, PolyMedicure Ltd, Troge Medical GmbH, Vygon SA, ICU Medical Inc, ConvaTec Group plc, Baxter International Inc

Get The Full Malignant Pleural Effusion Market Report:

https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report

Which Region Has The Greatest Market Share In The Malignant Pleural Effusion Market?

North America was the largest region in the malignant pleural effusion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Malignant Pleural Effusion Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report

Browse Through More Reports Similar to the Global Malignant Pleural Effusion Market 2026, By The Business Research Company

Acoustic Neuroma Market Report 2026

https://www.thebusinessresearchcompany.com/report/acoustic-neuroma-global-market-report

Paraganglioma Market Report

https://www.thebusinessresearchcompany.com/report/paraganglioma-global-market-report

Adult Malignant Glioma Therapeutics Market Report

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model